​

Sagimet Biosciences (SGMT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SGMT Stock Forecast

Sagimet Biosciences (SGMT) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $18.00, with a high of $18.00 and a low of $18.00. This represents a 62.31% increase from the last price of $11.09.

- $4 $8 $12 $16 $20 High: $18 Avg: $18 Low: $18 Last Closed Price: $11.09

SGMT Stock Rating

Sagimet Biosciences stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

SGMT Price Target Upside V Benchmarks

TypeNameUpside
StockSagimet Biosciences62.31%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts112
Avg Price Target$18.00$18.00$13.00
Last Closing Price$11.09$11.09$11.09
Upside/Downside62.31%62.31%17.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26181--10
Aug, 26-81--9
Jul, 26-81--9
Jun, 26-81--9
May, 26181--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026Eliana MerleBarclays$18.00$10.7168.07%62.31%
Jan 27, 2026Eliana MerleBarclays$8.00$6.0931.36%-27.86%
Jun 28, 2024Andrea TanGoldman Sachs$6.00$4.1145.99%-45.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2026Cantor FitzgeraldOverweightinitialise
Sep 09, 2026BarclaysOverweightupgrade
Aug 14, 2026CitigroupOutperformOutperformhold
Aug 14, 2026CitigroupMarket OutperformMarket Outperformhold
May 01, 2026OppenheimerOutperformOutperformhold
Apr 28, 2026Cowen & Co.BuyBuyhold
Mar 26, 2026Rodman & RenshawBuyinitialise
Feb 03, 2026GuggenheimBuyinitialise
Nov 14, 2025CitigroupOutperformOutperformhold
Aug 11, 2025WedbushOutperforminitialise

Financial Forecast

EPS Forecast

$-40 $-32 $-24 $-16 $-8 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.53$-1.45$-1.58---
Avg Forecast$-37.28$-1.49$-3.34$-4.34$-5.83$-3.58
High Forecast$-37.28$-1.42$-2.83$-0.95$-4.37$-3.58
Low Forecast$-37.28$-1.65$-4.10$-6.80$-7.68$-3.58
Surprise %-95.90%-2.68%-52.69%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.00M-----
Avg Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
High Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
Low Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
Surprise %------

Net Income Forecast

$-400M $-320M $-240M $-160M $-80M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.88M$-45.57M$-51.04M---
Avg Forecast$-389.91M$-16.05M$-36.21M$-40.53M$-63.03M$-37.41M
High Forecast$-389.91M$-14.89M$-29.55M$-9.97M$-45.69M$-37.41M
Low Forecast$-389.91M$-17.21M$-42.87M$-71.09M$-80.36M$-37.41M
Surprise %-92.85%183.86%40.95%---

SGMT Forecast FAQ

Is Sagimet Biosciences stock a buy?

Sagimet Biosciences stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Sagimet Biosciences is a favorable investment for most analysts.

What is Sagimet Biosciences's price target?

Sagimet Biosciences's price target, set by 8 Wall Street analysts, averages $18 over the next 12 months. The price target range spans from $18 at the low end to $18 at the high end, suggesting a potential 62.31% change from the previous closing price of $11.09.

How does Sagimet Biosciences stock forecast compare to its benchmarks?

Sagimet Biosciences's stock forecast shows a 62.31% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Sagimet Biosciences over the past three months?

  • September 2026: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 88.89% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 0% Strong Buy, 88.89% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Sagimet Biosciences’s EPS forecast?

Sagimet Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.34, marking a 174.68% increase from the reported $-1.58 in 2025. Estimates for the following years are $-5.83 in 2027, and $-3.58 in 2028.

What is Sagimet Biosciences’s revenue forecast?

Sagimet Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $21K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $29.4M, and $100.68M for 2028.

What is Sagimet Biosciences’s net income forecast?

Sagimet Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-40.53M, representing a -20.59% decrease from the reported $-51.038M in 2025. Projections indicate $-63.025M in 2027, and $-37.413M in 2028.